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Abstract. The purposes of this study are to estimate cumulative incidence and risk ratio 
for osteonecrosis of the jaw (ONJ) after tooth extraction in patients with and without 
administration of bisphosphonates (BP) and to identify potential risk factors for 
bisphosphonate-induced osteonecrosis of the jaw (BIONJ). A cohort study was 
conducted in all patients undergoing tooth extraction at a university hospital in Japan 
from April 2006 to June 2009. Of 3216 patients, 126 had BP administration, of whom 5 
(3.9%, 95% confidence interval (CI): 1.2 to 9.2) developed ONJ, versus 1 (0.032%, 
95% CI: 0.00081 to 0.18) among 3090 patients without BP administration. BP 
administration was associated with the development of ONJ after tooth extraction, with 
an unadjusted risk ratio of 122.6 (95% CI: 14.4 to 1041.8). When stratified by age and 
route of BP administration, the risk ratio for ONJ patients aged 65 years or older with 
intravenous BP administration compared to those without was 200.2 (95% CI: 23.8 to 
1679.4, P < 0.001). Patients receiving BP showed a significant association between the 
incidence of BIONJ and alveolar bone loss score. The risk of ONJ is higher in patients 
with than without BP administration, particularly intravenous administration. Severe 






Bisphosphonates (BP) are used for the treatment of a range of bone involvement, such 
as osteoporosis or bone metastases of malignant cancer, and their efficacy in preventing 
further bone damage, reducing bone pain, and increasing bone mineral density has been 
confirmed. Nevertheless, in 2003 Marx reported bisphosphonate-related osteonecrosis 
of the jaw or bisphosphonate-induced osteonecrosis of the jaw (BIONJ), as a side effect 
of BP treatment
1
. However, the incidence and mechanism of BIONJ have not been 
accurately determined. 
Since that initial report, the association between BP exposure and the incidence of 
osteonecrosis of the jaw (ONJ) has been clarified in several case series, reviews, 
epidemiologic studies and clinical trials
2-11
, which reported a prevalence of BIONJ 
ranging from 0.7% to 18.6% on intravenous
5-7
 and 0.01% to 4.3% on oral 
administration
8, 9
. Nevertheless, the low incidence of ONJ among BP-naïve patients has 
prevented any direct estimation of the risk ratio of ONJ among patients receiving BP. 
Black et al. indentified only 1 patient with possible ONJ among 3852 postmenopausal 
women during a 3-year period
10
. In their 6-year population-based cohort study using 
medical claims data, Wilkinson et al. found that 0.30% of naïve patients had been 





Tooth extraction has been reported to be the main initiating factor and one of the 
most common risk factors for BIONJ among patients receiving BP (approximately 86% 
of cases)
 8, 12, 13
, and relative risk of BIONJ in these patients is 5.3 to 53 times higher 
than in BP patients who do not experience tooth extraction
5, 14, 15
. A current guideline 
recommends non-surgical treatment rather than tooth extraction in dental patients at 
high risk of BIONJ
16
, but given that bacterial infection is itself reported as a critical risk 
factor for BIONJ
16
, avoiding extraction might be problematic in cases in which the 
bacterial infection remains. Further, information on the incidence or risk factors for 
BIONJ after tooth extraction among patients receiving BP is limited. A better 
understanding of this condition, particularly with regard to risk factors and incidence, 
will be helpful to dentists in the care of patients receiving treatment with BP. 
The purpose of this study was to estimate the cumulative incidence and risk ratio for 
ONJ after tooth extraction in patients with and without administration of BP, and to 
identify potential risk factors for BIONJ, including oral status. 
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Materials and methods 
Study design and cohort 
We conducted a retrospective analysis of patients who had undergone tooth extraction 
between April 2006 and June 2009 at the Department of Oral and Maxillofacial Surgery, 
Kyoto University Hospital. Patients were identified using administrative data, and 
dental and medical records were reviewed from January 2010 to August 2010. This 
study protocol was approved by the Ethics Committee of Kyoto University Graduate 
School and Faculty of Medicine. 
 
Definition and diagnosis of ONJ 
Inclusion was restricted to patients aged 20 years or older. ONJ in this study was 
diagnosed by the presence of exposed bone in the maxillofacial region that had persisted 
for more than 8 weeks, in reference to diagnostic criteria formulated by the American 
Association of Oral and Maxillofacial Surgeons
16
. Diagnoses were determined 
independently by two oral and maxillofacial surgeons. Among patients undergoing tooth 
extraction at our institution, we excluded cases of tooth extraction in patients with 
metastatic tumors to the oral region; signs of osteomyelitis or exposed bone in the 
maxillofacial region before extraction; any history of craniofacial radiation therapy; and 
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patients for whom panoramic radiographs before extraction were not available. Cases 
with diagnostic disagreement were then discussed. Finally, ONJ cases with diagnostic 
disagreement were regarded as non-ONJ cases and analyzed with the non-ONJ patients. 




For each chart reviewed, we collected the following information: demographics; 
medical history; test results; and potential risk factors associated with ONJ, namely the 
use of steroids, chemotherapy (including anticancer agents, immunosuppressive agents 
and thalidomide), current smoking status, current alcohol intake, diabetes, and details 
regarding BP treatment (indication, type, dose, duration). Recommended regimens for 
oral BP administration in the treatment of osteoporosis in Japan are etidronate sodium, 
200 mg per day (Didronel
 ®










), while those for intravenous administration in the treatment of 
osteolytic bone metastases of malignant cancer, multiple myeloma, or hypercalcemia of 
malignancy are incadronate, 10 mg per time (Bisphonal
®
); pamidronate, 30 - 45 mg for 
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hypercalcemia of malignancy, or 90 mg every 4 week for osteolytic bone metastases of 
malignant cancer (Aredia
®
); and zoledronic acid, 4 mg every 4 week (Zometa
®
). 
Intravenous BP have not been approved for osteoporosis in Japan. 
For patients treated with BP in the hospital, we entered these medications into the 
electronic medical record system to obtain the type and duration of BP administration, 
and the number of patients administered them to estimate the incidence of BIONJ. For 
patients treated with BP in other hospitals, we reviewed the record of their first 
examination at our hospital, at which we recorded the type and duration of BP 
administration as obtained from the referring physician by letter. 
 
Measurement of oral status 
Using the patient’s panoramic radiograph before tooth extraction, an experienced 
examiner calculated the DMF index and severity of alveolar bone loss. The DMF index, 
which comprises the number of decayed (D), missing (M), and filled (F) teeth, has been 
established as a key measurement of caries experience in dental epidemiology
17
. In 
addition, the severity of alveolar bone loss was measured to examine periodontal status 
as a percentage of missing bone at the mesial and distal surfaces of each tooth present
18
. 
Severity was estimated from (a-b)/a×100 (%) using the panoramic radiograph (a, 
9 
 
distance from radiographic apex to cement-enamel junction (mm); b, distance from 
radiographic apex to interproximal alveolar bone crest (mm)). If the location of the 
cemento-enamel junction was obscured by interproximal fillings, the cervical margin of 
these fillings was chosen as standard. If the cervical margin of these fillings was 
obscured, bone loss height was characterized as unmeasurable. Each tooth surface was 
assigned a score corresponding to a bone loss of 0% to 24%, 25% to 49%, 50% to 74%, 
and 75% to 100%, respectively. These measurements were then averaged to yield a 






The incidence of ONJ was calculated using the cumulative incidence method, which is 
defined as the number or proportion of a cohort of people who experience the onset of 
ONJ during a specified time interval
20
. In the calculation of the CI for incidence, the 
Poisson distribution was used. Medians for continuous variables were compared using 
the Wilcoxon rank-sum test. Proportions across levels of categorical variables were 
compared using the Fisher exact test. Risk ratios were calculated for all dichotomous 
variables and Wald CIs were calculated
20
. All P values were two sided at a significance 
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level of 5%. For missing data, available-case analysis was performed in addition to 
multiple imputation analysis. All statistical analysis was performed using Stata 11.2 




A total of 3240 patients underwent tooth extraction at our institute. After exclusion of 8 
patients with a history of craniofacial radiation therapy and 16 without a panoramic 
radiograph, 3216 (99.2%) eligible patients were entered into the analysis. Patient 
characteristics are summarized in Table 1. A total of 126 patients (3.9%) had received 
BP; among the 103 women (81.7%), 86 (83.5%) were treated with oral BP and 17 
(16.5%) with intravenous BP, while among the 23 men, 13 (56.5%) received oral and 
10 (43.5%) received intravenous BP. Seven patients were diagnosed with both 
osteoporosis and breast cancer, all of whom had been treated with oral BP. The total 
number of patients without BP administration was 3090 (96.0%), of whom 51.8 % were 





Cumulative incidence of ONJ after tooth extraction 
Five of the 126 patients receiving BP developed ONJ (3.9%, 95% CI: 1.2 to 9.2), versus 
1 (0.032%, 95% CI: 0.00081 to 0.18) of the 3090 without BP administration. Individual 
data of these 6 patients with ONJ are shown in Table 2. The cumulative incidence of 
ONJ among patients with BP administration was significantly higher than that among 
those without (P < 0.001). The crude risk ratio for ONJ after tooth extraction for 
patients with BP administration compared to those without was 122.6 (95% CI: 14.4 to 
1041.8). By route of administration, cumulative incidence was 1.0% (95% CI: 0.025 to 
5.6) among patients treated with oral BP and 14.8% (95% CI: 4.0 to 37.9) in those 
treated with intravenous BP. The risk ratio for ONJ was 31.2 (95% CI: 1.9 to 495.4) 
among patients treated with oral BP and 457.7 (95% CI: 52.8 to 3962.7) in those treated 
with intravenous BP. Large differences were seen in age and prevalence of cancer or 
osteoporosis between BP and BP-naïve patients. We therefore performed stratified 
analysis by age and route of BP administration to estimate risk ratios for ONJ to control 
for these factors. (Table 3). Among patients aged 65 years or older (median 73, range 65 
to 94), the risk ratio for ONJ for patients with oral or intravenous BP administration 
compared to those without was 12.9 (95% CI: 0.82 to 204.6, P = 0.138) or 200.2 (95% 




Association with possible risk factors for BIONJ after tooth extraction 
We next investigated potential risk factors associated with BIONJ among patients with 
BP administration. The incidence of BIONJ was significantly associated with the type 
of BP (P = 0.007) but not with the other potential risk factors (Table 4). The crude risk 
ratio for intravenous compared with oral BP administration was 14.6 (95% CI: 1.7 to 
125.8). The type, dosage and duration of intravenous BP administration is shown in 
Table 5. Median duration in patients with BIONJ (13.5, range: 7 to 49 months) was 
longer than that in patients without BIONJ (7.5, range: 1 to 96 months), but this 
difference was not significant. Regarding oral BP, etidronate, alendronate and 
risedronate were given as single agents to 4 (4.0%), 54 (54.5%), and 31 patients 
(31.3%), respectively, while the rest (10.2 %) received a series of double BP agents.  
Regarding oral status among patients receiving BP, we found a significant 
association between the incidence of BIONJ and bone loss score but not DMF index. 
The median bone loss score among BIONJ patients was significantly higher than that 
among those without BIONJ (P = 0.024) (Table 4): namely, while median bone loss 
score among those without BIONJ was 1.3 (interquartile range 1.1 to 1.6) and the 
prevalence of severe periodontal status was 7.4%, median score among BIONJ patients 
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was 1.6 (interquartile range 1.5 to 1.9) and the prevalence of severe periodontal status 
was 20.0%. Similarly, this association was significantly found among patients aged 65 
years or older (median, 1.4 vs. 1.6, P = 0.034). 
 
Missing data 
Potential risk factors were not available for eight patients, namely the duration of BP 
administration for one patient and current alcoholic intake and current smoking for 
seven patients. We therefore performed available-case analysis (Table 4 and Table 5). 
Additionally, we also performed multiple imputation analysis, but the results did not 
change from those of available-case analysis (data not shown). 
 
Discussion 
We found that the cumulative incidence of ONJ among patients who had received BP 
administration was significantly higher than that among patients who had not received 
this treatment (crude risk ratio 122.6, 95% CI: 14.4 to 1041.8). To our knowledge, this 
study is the first cohort study to evaluate the cumulative incidence and risk ratio for 
ONJ after tooth extraction among patients with or without BP administration. 
Additionally, risk ratio for ONJ was particularly elevated in the subpopulation of 
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patients with intravenous BP administration. Age–stratified analysis showed no 
significant association between the incidence of ONJ after tooth extraction and oral BP 
among elderly patients aged over 65 years old, but a significant association with 
intravenous BP administration (risk ratio 200.2, 95% CI: 23.8 to 1679.4). These results 
indicate that intravenous BP may be associated with an increased risk of ONJ after tooth 
extraction among elderly patients over 65 years old. Dental practice-based research 
network (DPBRN) reported an unadjusted odds ratio for ONJ for patients with oral BP 
administration compared to those without of 15.5 (95% CI: 6.0 to 38.7) in two 
health-care organizations, regardless of a history of tooth extraction
21
. The impact of 
oral BP on the risk of ONJ after tooth extraction requires further investigation. 
   In the DPBRN study, the investigators had so little hospital information that they 
could not estimate the risk ratio of intravenous BP
21
. In our study, although a 
single-center study, we were able to collect detailed BP administrative data from the 
hospital database and estimate the risk ratio stratified by the route of BP administration. 
In addition, oral and maxillofacial surgeons followed up all patients after tooth 
extraction, diagnosed ONJ, and excluded patients with non BP-induced ONJ. This 
extraction of detailed information and manual confirmation of ONJ likely improved the 
reliability of our results. 
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Previous studies have reported that preventative dental treatment decreased BIONJ 
risk among patients with intravenous BP administration
22-24
. All patients who consulted 
the outpatient clinic of our department before BP administration underwent an oral 
examination, screening for periodontal disease, and oral cleaning. For patients receiving 
BP, particularly intravenous BP, an extensive oral examination was performed and 
preventive dental treatment was conducted if needed. When tooth extraction was 
required following ineffective conservative treatment, preventive dental treatment was 
performed before extraction in all patients receiving BP, and extraction was conducted 
with particular care and antibiotic use, with complete wound closure when possible.  
The estimated incidence of BIONJ associated with tooth extraction in the literature 
ranges from 8.3% to 40%
5, 15, 25
. The present study found a cumulative incidence of 
BIONJ after extraction at 42 months among all patients receiving BP and those 
receiving intravenous BP of 3.9% and 14.8%, respectively. Saia et al. reported that 5 of 
60 patients receiving BP by either route developed BIONJ after tooth extraction (8.3%) 
within 12 months
25
. In a large cohort of 3994 patients with intravenous BP 
administration, Hoff et al. reported that 16 (10.5%) of 152 patients with tooth extraction 
developed BIONJ within 90 months, while in 1621 patients receiving intravenous BP
5
, 
Vahtsevanos et al. reported that 46 of 115 patients with a history of tooth extraction 
16 
 
developed BIONJ (40%) within 106 months
15
. The results of our present study are 
consistent with these other studies which also employed positive preventive dental 
treatment before tooth extraction, and better than that of the study which did not 
describe the use of preventive care
15
. In addition, Mawardi et al. reported that bacterial 
infection at tooth extraction sites caused diminished keratinocyte growth factor 
expression in gingival fibroblasts, leading to a delay in the epithelial wound-healing 
process in vitro and in vivo experiments
26
. These results are consistent with the 
hypothesis that poor oral hygiene might be associated with an increased risk of BIONJ 
after tooth extraction. Preventive and therapeutic treatment of oral bacterial infection 
before extraction might be important in preventing BIONJ in patients with BP 
administration. 
Periodontal disease, an infection caused by oral bacteria, is characterized by 
inflammation that leads to alveolar bone loss
27
. In this study, we found that not only 
intravenous BP administration but also the loss of alveolar bone was associated with an 
increased risk of BIONJ after tooth extraction. Given that all patients with BP 
administration underwent preventive and therapeutic treatment of oral bacteria before 
tooth extraction and that any effect of infection at the time of extraction was accordingly 
minimum, our findings suggest that previous inflammation of periodontal tissue may 
17 
 
predispose to BIONJ after tooth extraction. 
Several limitations of this study warrant mention. First, large differences were seen 
in age and prevalence of cancer or osteoporosis between BP and BP-naïve patients. We 
therefore performed stratified analysis by age and route of BP administration to estimate 
risk ratios for ONJ to control for these factors. However, due to the limited number of 
events, we were unable to estimate relative risks adjusted for the other potential risk 
factors such as steroid use or smoking, and the 95% CIs were wide. This prevents the 
drawing of any reliable conclusions from the results, and indicates the need to evaluate 
possible risk factors or relative risks in a larger number of patients with ONJ, or to 
conduct a case-control study. Second, selection bias is inherent to single-center studies, 
and the present study was additionally subject to inherent referral bias toward the 
selection of more severe cases, given that our department is a lead institution for oral 
and maxillofacial surgery in Kyoto City. A positive aspect of this latter limitation, 
however, is that almost all patients consult our department again in the event of 
subsequent problems at the tooth extraction site. Additionally, ONJ is an uncommonly 
encountered clinical condition, and such patients are likely to be referred to our clinic to 
establish a diagnosis. The impact of selection bias is thus somewhat unclear. Subsequent 
multicenter regional (or national) studies would be required to address this bias. Third, 
18 
 
we were unable to eliminate the possibility that some of the patients who developed 
ONJ might have had unidentified ONJ in the submucosa at the time of tooth extraction, 
hampering assessment of the impact of tooth extraction on ONJ development. A 
comprehensive understanding of the mechanism of ONJ therefore awaits additional 
studies. 
In conclusion, BP administration, particularly intravenous administration, is 
associated with an increased risk of ONJ after tooth extraction. Severe alveolar bone 
loss might be a risk factor for BIONJ after tooth extraction. This study provides 
important information for physicians and dentists concerned with the prevention of ONJ 











This study protocol was approved by the Ethics Committee of Kyoto University 
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Table 1. Patient characteristics 
BP = bisphosphonate; N.A. = not applicable 










Characteristic BP administration 
 Yes (n = 126) No (n = 3090) 
Age, years 
  Median 66.0 39.0 
  Range 26 - 88 20 - 94 
Sex (%) 
  Male 23 (18.3) 1490 (48.2) 
  Female 103 (81.7) 1600 (51.8) 
Primary disease (%) 
Osteoporosis* 99 (78.6) 74 (2.4) 
Breast cancer* 13 (10.3) 61 (2.0) 
Multiple myeloma 11 (8.7)  5 (0.2) 
Prostate cancer 1 (0.8) 41 (1.3) 
Kidney cancer 3 (2.4)   1 (0.03) 
Other cancer 6 (4.8) 184 (5.6) 
Route of BP administration (%) 
Oral 99 (78.6) N.A. 
Intravenous 27 (21.4) N.A. 
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 Table 2. Demographic and clinical characteristics of ONJ patients  
ONJ = Osteonecrosis of the jaw; BP = bisphosphonate; A = alendronate; P = pamidronate; Z = zoledronic acid; 
Sex Age Primary disease Type of BP Dosage of BP (mg) Duration of BP (mon) Other risk factors Cure and prognosis 
F 75 Osteoporosis A 1990 13 None Sequestrectomy, 
       healing 
        
F 75 Breast cancer P 1455 45 Chemo therapy Currettage,   
   Z 16 4  nonhealing 
        
F 68 Multiple myeloma P 1305 19 Thalidmide Sequestrectomy,  
      Steroid healing 
        
M 75 Prostate cancer Z 32 8 Chemo therapy Die of primary disease  
        
        
M 67 Kidney cancer Z 28 7 None Sequestrectomy,  
       healing 
        
M 73 None None - - None Sequestrectomy,  
       healing 
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Table 3. Stratified analysis of osteonecrosis of the jaw after tooth extraction 
The Fisher exact test was used to compare differences in the incidence of 
osteonecrosis of the jaw between patients with and without BP administration. 
Statistically significant P values appear in bold. 
ONJ = Osteonecrosis of the jaw; CI = confidence interval; BP = bisphosphonate; IV 
= intravenous; ref = reference; N.A. = not applicable 






Risk ratio (95% CI) P value 
Total 
BP (+) 5 (83.3) 121 (3.8) 126 122.6 (14.4-1041.8) < 0.001 
BP (-) 1 (16.7) 3089 (96.2) 3090 1.0 (ref)  
BP-stratified  
Oral BP (+) 1 (16.7) 98 (3.1)  99 31.2 (1.9-495.4) 0.061 
IV BP (+) 4 (66.6) 23 (0.7) 27 457.7 (52.8-3962.7) < 0.001 
BP (-) 1 (16.7) 3089 (96.2) 3090 1.0 (ref)  
Age-stratified (65 years >=) 
BP (+) 5 (16.7) 63 (8.3) 68 51.5 (6.1-434.8) < 0.001 
BP (-) 1 (83.3) 700 (91.7) 701 1.0 (ref)  
Age-stratified (65 years <) 
BP (+) 0 58 (2.4) 58 N.A N.A 
BP (-) 0 2389 (97.6) 2389 1.0 (ref)  
BP- and age-stratified (65 years >=) 
Oral BP (+) 1 (16.7) 53 (7.0) 54 12.9 (0.82-204.6) 0.138 
IV BP (+) 4 (66.6) 10 (1.3) 14 200.2 (23.8-1679.4) < 0.001 
BP (-) 1 (16.7) 700 (91.7) 701 1.0 (ref)  
BP- and age-stratified (65 years <) 
Oral BP (+) 0 45 (1.8) 45 N.A. N.A. 
IV BP (+) 0 13 (0.53) 13 N.A. N.A. 
BP (-) 0 2389 (97.6) 2389 1.0 (ref)  
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Table 4. Potential risk factors for osteonecrosis of the jaw after tooth extraction 
 Bisphosphonate-induced osteonecrosis of the jaw 
Variable Yes (n = 5) No (n = 121) RR (95%CI) P value 
Sex - no. (%) 
Male 2 (40.0) 21 (17.4) 2.9 (0.52-16.8) 0.225 
Female 3 (60.0) 100 (82.6) 1.0 (ref)  
Age 
Median 75.0 65.0 N.A. 0.133 
Range 67-77 26-88   
Administration route - no. (%) 
Intravenous 4 (80.0) 23 (19.0) 14.6 (1.7-125.8) 0.007 
Oral 1 (20.0) 98 (81.0) 1.0 (ref)  
Steroid use - no. (%) 
Yes 2 (40.0) 54 (44.6) 0.83 (0.14-4.8) 1.000 
No 3 (60.0) 67 (55.4) 1.0 (ref)  
Chemotherapy use - no. (%) 
Yes 3 (60.0) 23 (19.0) 5.7 (1.0-32.7) 0.059 
No 2 (40.0) 98 (81.0) 1.0 (ref)  
Diabetes - no. (%) 
Yes 0 (0) 9 (7.4) N.A. N.A. 
No 5 (100) 112 (92.6)   
Current smoking - no. (%)* 
Yes 0 (0) 21 (18.4) N.A. N.A. 
No 5 (100) 93 (81.6)   
Current alcohol intake - no. (%)* 
Yes 1 (20.0) 29 (25.4) 0.74 (0.086-6.3) 1.000 
No 4 (80.0) 85 (74.6) 1.0 (ref)  
DMF count 
median 21 19 N.A. 0.548 
range 13 - 28 0 - 28   
D count 
median 2 1 N.A. 0.085 
range 1 - 4 0 - 15   
M count 
median 7 5 N.A. 0.209 




median 10 10 N.A. 0.910 
range 4 - 14 0 - 25   
Bone loss score 
median 1.6 1.3 N.A. 0.022 
range 1.5 - 2.2 1.0 - 3.5   
P values were calculated using the Fisher exact test or Wilcoxon rank-sum test. 
The Fisher exact test was used to compare differences in the presence of potential 
risk factor between patients with and without BIONJ. 
Statistically significant P values appear in bold. 
RR = risk ratio; CI = confidence interval; ref = reference; N.A. = not applicable; 
D = decayed teeth; M = missing teeth; F = filling teeth 


















Table 5. Type, dosage and duration of intravenous BP administration 
P values were calculated using the Wilcoxon rank-sum test. 
* Data were not available for one patient. 
BP = bisphosphonate; I = incadronate; P = pamidronate; Z = zoledronic acid;  
IV = intravenous 
 
 Bisphosphonate-induced osteonecrosis of the jaw 
Dosage of IV BP administration (mg) 
 Yes (n = 4) No (n = 22*)  
Single-drug administration 
Incadronate    
    no. 0 1  
    median (range) 0 40  
Pamidronate    
    no. 1 2  
    median (range) 1305 30 (15 - 45)  
Zoledronic acid    
    no. 2 11  
    median (range) 30 (28 - 32) 44 (4 - 104)  
Combined-drug administration 
Incadronate + Pamidronate    
    no. 0 2  
    median (range) 0 I: 1640 (210 - 3070)  
  P: 1608 (470 - 2745)  
Pamidronate + Zoledronic acid    
    no. 1 6  
    median (range) P: 1455 P: 75 (30 - 2160)  
 Z: 16 Z: 50 (12 -56)  
Duration of IV BP administration (month) 
 Yes (n = 4) No (n = 22*) P value 
    median (range) 13.5 (7 - 49) 7.5 (1 - 96) 0.333 
